EMERGENT BIOSOLUTIONS INC. Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable
EMERGENT BIOSOLUTIONS INC. (EBS) reported Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable of $4.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes payable, net of income taxes receivable for the quarter ending 2026-06-30 was -$300.00K, a 104.41% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes payable, net of income taxes receivable for the quarter ending 2026-03-31 was $4.60M.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes payable, net of income taxes receivable for the quarter ending 2025-12-31 was -$6.30M.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes payable, net of income taxes receivable for the quarter ending 2025-09-30 was $6.20M, a 40.95% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes payable, net of income taxes receivable for fiscal 2025 was -$1.70M, a 107.30% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes payable, net of income taxes receivable for fiscal 2024 was $23.30M.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes payable, net of income taxes receivable for fiscal 2023 was -$16.20M, a 156.45% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. increase (decrease) in income taxes payable, net of income taxes receivable for fiscal 2022 was $28.70M.
| Period end | Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable 12 month | Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $4.30M 10-Q · filed 2026-08-06 | -$2.00M derived: sum of 3 quarters · filed 2026-08-06 | $4.20M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $4.60M 10-Q · filed 2026-05-01 | -$1.70M derived: sum of 2 quarters · filed 2026-05-01 | $4.50M derived: sum of 3 quarters · filed 2026-05-01 | $11.30M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | -$6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$100.00K derived: sum of 2 quarters · filed 2026-02-27 | $6.70M derived: sum of 3 quarters · filed 2026-08-06 | -$1.70M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $6.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $13.00M derived: sum of 2 quarters · filed 2026-08-06 | $4.60M 10-Q · filed 2025-10-30 | $1.30M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $6.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.60M 10-Q · filed 2026-08-06 | -$4.90M derived: sum of 3 quarters · filed 2026-08-06 | $5.60M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$8.40M 10-Q · filed 2026-05-01 | -$11.70M derived: sum of 2 quarters · filed 2026-05-01 | -$1.20M derived: sum of 3 quarters · filed 2026-05-01 | -$1.20M derived: sum of 4 quarters · filed 2026-05-01 | |
| 2024-12-31 | -$3.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $7.20M derived: sum of 2 quarters · filed 2026-02-27 | $7.20M derived: sum of 3 quarters · filed 2026-02-27 | $23.30M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $10.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $10.50M derived: sum of 2 quarters · filed 2025-10-30 | $26.60M 10-Q · filed 2025-10-30 | $13.90M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $16.10M 10-Q · filed 2025-08-07 | $3.40M derived: sum of 3 quarters · filed 2026-02-27 | -$14.30M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | $16.10M 10-Q · filed 2025-05-08 | $3.40M derived: sum of 2 quarters · filed 2026-02-27 | -$14.30M derived: sum of 3 quarters · filed 2026-02-27 | -$13.00M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | -$12.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$30.40M derived: sum of 2 quarters · filed 2026-02-27 | -$29.10M derived: sum of 3 quarters · filed 2026-02-27 | -$16.20M 10-K · filed 2026-02-27 | |
| 2023-09-30 | -$17.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$16.40M derived: sum of 2 quarters · filed 2024-11-07 | -$3.50M 10-Q · filed 2024-11-07 | $76.20M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $14.20M 10-Q · filed 2024-08-07 | $93.90M derived: sum of 3 quarters · filed 2025-03-04 | $89.30M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-03-31 | $12.90M 10-Q · filed 2024-05-02 | $92.60M derived: sum of 2 quarters · filed 2025-03-04 | $88.00M derived: sum of 3 quarters · filed 2025-03-04 | $47.10M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2022-12-31 | $79.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $75.10M derived: sum of 2 quarters · filed 2025-03-04 | $34.20M derived: sum of 3 quarters · filed 2025-03-04 | $28.70M 10-K · filed 2025-03-04 | $28.60M 10-K · filed 2023-03-01 |
| 2022-09-30 | -$4.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-12-11 | -$45.50M derived: sum of 2 quarters · filed 2023-12-11 | -$51.00M 10-Q · filed 2023-12-11 | ||
| 2022-06-30 | -$40.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$46.40M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | -$5.50M 10-Q · filed 2023-05-10 | ||||
| 2021-12-31 | -$31.30M 10-K · filed 2024-03-08 | -$32.40M 10-K · filed 2023-03-01 | |||
| 2020-12-31 | $6.00M 10-K/A · filed 2023-12-11 | $1.10M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |